Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 2/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.48 |
| ▸ | DRD2 | P14416 | 3/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | DRD1 | P21728 | 1/20 | 0.36 |
| ▸ | DRD4 | P21917 | 1/20 | 0.36 |
| ▸ | DRD5 | P21918 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.34 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6929073 | 0.85 | HRH3 (0.49) | ESR1HRH3DRD2SLC6A4KDM2B | |
| SCHEMBL18200131 | 0.83 | CARM1 (0.49) | ESR1HRH3DRD2SLC6A4DRD1 | |
| SCHEMBL16291964 | 0.80 | HRH3 (0.41) | HRH3SLC6A4 | |
| SCHEMBL18170287 | 0.80 | HRH3 (0.45) | ESR1HRH3DRD2DRD1DRD4 | |
| SCHEMBL26031470 | 0.74 | NAAA (0.39) | ESR1HRH3SLC6A4 | |
| SCHEMBL20569858 | 0.74 | DUT (0.40) | ESR1HRH3 | |
| SCHEMBL20447842 | 0.73 | SLC6A4 (0.44) | ESR1HRH3DRD2SLC6A4 | |
| SCHEMBL17736168 | 0.73 | PSMB1 (0.51) | ESR1HRH3 | |
| SCHEMBL14862790 | 0.72 | CHRM3 (0.37) | HRH3SLC6A4 | |
| SCHEMBL20205993 | 0.72 | SLC6A4 (0.49) | ESR1HRH3SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170362210-A1 | ANTI-ESTROGENIC COMPOUNDS | PFIZER INC. (US) | 2017-12-21 | — | — | US | disclosed |
| WO-2016174551-A1 | ANTI-ESTROGENIC COMPOUNDS | PFIZER INC. (US) | 2016-11-03 | — | — | WO | disclosed |
| US-20160311805-A1 | ANTI-ESTROGENIC COMPOUNDS | PFIZER INC. (US) | 2016-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170362210-A1 | ANTI-ESTROGENIC COMPOUNDS | ESR1, ESRRA, ESR2 | ESR1 1/4885HRH3 294/4885DRD2 1249/4885 |
| US-20160311805-A1 | ANTI-ESTROGENIC COMPOUNDS | ESR1, ESRRA, ESR2 | ESR1 1/4885HRH3 294/4885DRD2 1249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.